BioCryst Pharmaceuticals Inc. [NASDAQ: BCRX] gained 0.27% on the last trading session, reaching $11.15 price per share at the time. The company report on July 21, 2022 that BioCryst to Report Second Quarter 2022 Financial Results on August 4.
Top 5 Cheap Stocks to Own Right Now
While finding safe stocks with the potential for monster gains isn't always easy, we've found a few that could pay out well. In fact, within our report, "Top 5 Cheap Stock to Own Right Now", we have identified five stocks we believe could appreciate the most even if you just have $1,000 to invest.
Sign up here to get your free report now. .
BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will report its second quarter 2022 financial results Thursday, August 4, 2022.
BioCryst management will host a conference call and webcast at 8:30 a.m. ET that day to discuss the financial results and provide a corporate update.
BioCryst Pharmaceuticals Inc. represents 184.90 million in outstanding shares, while the company has a total market value of $2.08 billion with the latest information. BCRX stock price has been found in the range of $11.02 to $11.7492.
If compared to the average trading volume of 3.37M shares, BCRX reached a trading volume of 3168795 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Here is what top equities market gurus are saying about BioCryst Pharmaceuticals Inc. [BCRX]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for BCRX shares is $17.50 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on BCRX stock is a recommendation set at 2.30. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
Barclays have made an estimate for BioCryst Pharmaceuticals Inc. shares, keeping their opinion on the stock as Equal Weight, with their previous recommendation back on April 18, 2022. While these analysts kept the previous recommendation, BofA Securities dropped their target price from $21 to $14. The new note on the price target was released on April 11, 2022, representing the official price target for BioCryst Pharmaceuticals Inc. stock. Previously, the target price had yet another raise to $16, while Oppenheimer analysts kept a Outperform rating on BCRX stock.
The Average True Range (ATR) for BioCryst Pharmaceuticals Inc. is set at 0.58, with the Price to Sales ratio for BCRX stock in the period of the last 12 months amounting to 11.04.
Trading performance analysis for BCRX stock
BioCryst Pharmaceuticals Inc. [BCRX] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 0.90. With this latest performance, BCRX shares gained by 0.09% in over the last four-week period, additionally sinking by -27.27% over the last 6 months – not to mention a drop of -33.47% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for BCRX stock in for the last two-week period is set at 51.84, with the RSI for the last a single of trading hit 50.83, and the three-weeks RSI is set at 51.86 for BioCryst Pharmaceuticals Inc. [BCRX]. The present Moving Average for the last 50 days of trading for this stock 10.53, while it was recorded at 11.03 for the last single week of trading, and 12.92 for the last 200 days.
BioCryst Pharmaceuticals Inc. [BCRX]: A deeper dive into fundamental analysis
Operating Margin for any stock indicates how profitable investing would be, and BioCryst Pharmaceuticals Inc. [BCRX] shares currently have an operating margin of -113.08 and a Gross Margin at +94.88. BioCryst Pharmaceuticals Inc.’s Net Margin is presently recorded at -117.11.
BioCryst Pharmaceuticals Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 6.10 and a Current Ratio set at 6.30.
BioCryst Pharmaceuticals Inc. [BCRX]: An earnings per share (EPS) analysis
The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for BCRX. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for BioCryst Pharmaceuticals Inc. go to 15.20%.
An analysis of insider ownership at BioCryst Pharmaceuticals Inc. [BCRX]
There are presently around $1,460 million, or 73.40% of BCRX stock, in the hands of institutional investors. The top three institutional holders of BCRX stocks are: BLACKROCK INC. with ownership of 14,101,975, which is approximately -4.635% of the company’s market cap and around 0.40% of the total institutional ownership; VANGUARD GROUP INC, holding 13,207,040 shares of the stock with an approximate value of $147.26 million in BCRX stocks shares; and BAKER BROS. ADVISORS LP, currently with $141.73 million in BCRX stock with ownership of nearly 0% of the company’s market capitalization.
Positions in BioCryst Pharmaceuticals Inc. stocks held by institutional investors increased at the end of August and at the time of the August reporting period, where 112 institutional holders increased their position in BioCryst Pharmaceuticals Inc. [NASDAQ:BCRX] by around 26,977,169 shares. Additionally, 107 investors decreased positions by around 17,669,583 shares, while 40 investors held positions by with 86,285,599 shares. The mentioned changes placed institutional holdings at 130,932,351 shares, according to the latest SEC report filing. BCRX stock had 46 new institutional investments in for a total of 9,673,054 shares, while 31 institutional investors sold positions of 3,010,767 shares during the same period.